Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

bluebird bio : Announces September Investor Events

09/02/2020 | 08:08am EST

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:

  • 2020 Wells Fargo Virtual Healthcare Conference, Thursday, September 10, at 4:00 pm ET
  • Morgan Stanley 18th Annual Global Healthcare Conference, Tuesday, September 15, at 1:15 pm ET
  • BofA Global Healthcare Conference 2020, Friday, September 18, at 10:05 am ET

To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders including cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.


© Business Wire 2020
All news about BLUEBIRD BIO, INC.
11/24BLUEBIRD BIO : Announces Live Webcast to Review Clinical Data Presented at the A..
BU
11/19BLUEBIRD BIO : Corporate Presentation - November 2020
PU
11/10SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
11/10BLUEBIRD BIO : Announces November Investor Events
BU
11/05BLUEBIRD BIO : to Present Data from Gene and Cell Therapy Programs During the 62..
BU
11/04BLUEBIRD : 3Q Earnings Snapshot
AQ
11/04BLUEBIRD BIO : Management's Discussion and Analysis of Financial Condition and R..
AQ
11/04BLUEBIRD BIO : Reports Third Quarter 2020 Financial Results and Highlights Opera..
BU
11/04BLUEBIRD BIO, INC. : Results of Operations and Financial Condition, Financial St..
AQ
10/02BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Financials (USD)
Sales 2020 260 M - -
Net income 2020 -594 M - -
Net cash 2020 1 233 M - -
P/E ratio 2020 -4,44x
Yield 2020 -
Capitalization 2 869 M 2 869 M -
EV / Sales 2020 6,30x
EV / Sales 2021 14,0x
Nbr of Employees 1 171
Free-Float 99,5%
Chart BLUEBIRD BIO, INC.
Duration : Period :
bluebird bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLUEBIRD BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 80,05 $
Last Close Price 44,06 $
Spread / Highest target 231%
Spread / Average Target 81,7%
Spread / Lowest Target 13,5%
EPS Revisions
Managers
NameTitle
Nick Leschly President, Chief Executive Officer & Director
Daniel S. Lynch Chairman
Jason F. Cole Chief Operating & Legal Officer
William Denise Baird Chief Financial Officer
David M. Davidson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEBIRD BIO, INC.-50.74%2 869
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273